BioSig Announces Purchase Agreement with Kansas City Heart Rhythm Institute at Overland Park Regional Medical Center
July 07 2022 - 8:30AM
- OPRMC marks our first leasing agreement under new
program
- Company also inks national master agreement with one of
the largest U.S. healthcare systems
BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the
"Company"), a medical technology company advancing
electrophysiology workflow by delivering greater intracardiac
signal fidelity through its proprietary signal processing platform,
today announced that Kansas City Heart Institute at Overland Park
Regional Medical Center in Kansas City, U.S. has signed a purchase
agreement to acquire its PURE EP(T.M.) System.
Following its evaluation of BioSig's PURE EP(T.M.) System,
Overland Park Regional Medical Center (OPRMC) has signed an
agreement to purchase the technology under the terms of the
Company's new program. The agreement represents BioSig's first
commercial adoption since it announced the national launch of its
PURE EP ™ System, supported by The Company's new commercial
structure and clinical support teams. The agreement also represents
The Company's first national purchasing agreement.
"Establishing a contract with a leading national hospital
network is a milestone achievement for BioSig Technologies,"
commented Gray Fleming, Chief Commercialization Officer, BioSig
Technologies, Inc. "A leasing option provides a cost-effective
and efficient pathway for hospitals to acquire our technology. As a
Company that prioritizes physician experience and throughput, we
believe a leasing program supports the clinical evolution of PURE
EP as we continue upgrading and enhancing our technology based on
physician feedback."
"We are pleased to announce our first purchase agreement since
we transformed the commercial capabilities under new management,"
said Kenneth L. Londoner, Chairman and CEO of BioSig Technologies,
Inc. "The Company is excited about our clinical collaboration
with Dr. Lakkireddy and the physician faculty at Overland Park. As
physician advocates, we are proud of our commitment to and
alignment with the world-class arrhythmia program at Kansas City
Heart Rhythm Institute and thank them for their continued support
of our technology."
“This technology will be an instrumental part of Kansas City
Heart Rhythm Institute’s continued quest to provide superior world
class care for patients,” says Executive Medical Director for the
Kansas City Heart Rhythm Institute and Professor of Medicine at the
University of Missouri Columbia and University of Nevada Las Vegas
and Chief of Electrophysiology at Overland Park Medical Center,
Dhanunjaya DJ Lakkireddy, MD. “This technology could potentially
enhance our ability to improve efficacy and safety of heart rhythm
procedures and thereby positively impact workflow and subsequently,
patient outcomes.”
About Kansas City Heart Rhythm Institute
The Kansas City Heart Rhythm Institute at the HCA Midwest Health
Heart and Vascular Institute brings the highest quality clinical
care, research and arrhythmia education to Kansas City. There
are eight practicing Electrophysiologist. Locations include three
Electrophysiology Practice sites in the Greater Kansas City Area as
well as one outreach site location and Electrophysiology services
in four hospitals.
About Overland Park Regional Medical Center
Overland Park Regional Medical Center is a licensed 343-bed
facility offering acute medical care services to our patients. The
hospital campus features four medical office buildings, two
pharmacies, and the offices of more than 100 physicians.
Cardiovascular programs at OPRMC have received certification from
The American Association of Cardiovascular and Pulmonary
Rehabilitation (AACVPR). OPRMC's clinicians and physicians experts
excel in a wide range of interventional cardiology practices and
complex electrophysiology procedures, including Complex Arrhythmia
Management (Afib, VTACH, PVC, SVT), Convergent AFib Ablation (with
C.T. surgeon and E.P.), Leadless Pacemakers & Internal Cardiac
Defibrillators, and Left Atrial Appendage Closure.
About BioSig Technologies
BioSig Technologies is a medical technology company
commercializing a proprietary biomedical signal processing platform
designed to improve signal fidelity and uncover the full range of
ECG and intra-cardiac signals (www.biosig.com).
The Company's first product, PURE EP(T.M.) System, is a novel
signal processing and acquisition platform designed to extract
advanced diagnostic and therapeutic data that enhances physician
workflow and increases throughput. PURE EP(T.M.) was engineered to
address the limitations of existing E.P. technologies by empowering
physicians with superior signals and actionable insights.
To date, over 75 physicians have completed over 2500 patient
cases with the PURE EP(T.M.) System. The Company is in a national
commercial launch of the PURE EP(T.M.) System. The technology is in
regular use in some of the country's leading centers of excellence,
including Mayo Clinic, and Texas Cardiac Arrhythmia Institute at
St. David's Medical Center.
Clinical data acquired by the PURE EP(T.M.) System in a
multi-center study at centers of excellence including Texas Cardiac
Arrhythmia Institute at St. David's Medical Center was
recently published in the Journal of Cardiovascular
Electrophysiology and is available electronically with open access
via the Wiley Online Library. Study results showed 93% consensus
across the blinded reviewers with a 75% overall improvement in
intracardiac signal quality and confidence in interpreting PURE
EP(T.M.) signals over conventional sources.
Forward-looking Statements
This press release contains “forward-looking statements.” Such
statements may be preceded by the words “intends,” “may,” “will,”
“plans,” “expects,” “anticipates,” “projects,” “predicts,”
“estimates,” “aims,” “believes,” “hopes,” “potential” or similar
words. Forward- looking statements are not guarantees of future
performance, are based on certain assumptions and are subject to
various known and unknown risks and uncertainties, many of which
are beyond the Company’s control, and cannot be predicted or
quantified and consequently, actual results may differ materially
from those expressed or implied by such forward-looking statements.
Such risks and uncertainties include, without limitation, risks and
uncertainties associated with (i) market conditions and the
Company’s intended use of proceeds, (ii) the geographic, social and
economic impact of COVID-19 on our ability to conduct our business
and raise capital in the future when needed, (iii) our inability to
manufacture our products and product candidates on a commercial
scale on our own, or in collaboration with third parties; (iv)
difficulties in obtaining financing on commercially reasonable
terms; (v) changes in the size and nature of our competition; (vi)
loss of one or more key executives or scientists; and (vii)
difficulties in securing regulatory approval to market our products
and product candidates. More detailed information about the Company
and the risk factors that may affect the realization of
forward-looking statements is set forth in the Company’s filings
with the Securities and Exchange Commission (SEC), including the
Company’s Annual Report on Form 10-K and its Quarterly Reports on
Form 10-Q. Investors and security holders are urged to read these
documents free of charge on the SEC’s website at
http://www.sec.gov. The Company assumes no obligation to publicly
update or revise its forward-looking statements as a result of new
information, future events or otherwise.
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
55 Greens Farms Road, 1st Floor
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x133
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Apr 2023 to Apr 2024